Early research (Phase 1)Study completedNCT02268851
What this trial is testing
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Who this might be right for
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMantle Cell Lymphoma
Dana-Farber Cancer Institute 45